

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-640

APPROVAL LETTER



NDA 21-640

ISTA Pharmaceuticals, Inc.
Attention: Marvin J. Garrett
V.P. Regulatory Affairs, Quality & Compliance
15279 Alton Parkway, Suite 100
Irvine, California 92618

Dear Mr. Garrett:

Please refer to your new drug application (NDA) dated August 4, 2003, received August 5, 2003, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Vitrase® (hyaluronidase for injection) lyophilized, ovine.

We acknowledge receipt of your submissions dated September 10, December 2, 3, and 4, 2003; January 8, February 13, March 3, 5, 12, and 30, April 13, 14, 22 (2), 23 (2), 26 (2), 27, 30, and May 4, 2004.

This new drug application provides for the use of Vitrase® (hyaluronidase for injection) lyophilized, ovine as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the submitted text for the package insert, immediate container and carton labeling, dated May 4, 2004. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-640.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lori M. Gorski, Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Jonca C. Bull, M.D.
Director
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure